Publications by authors named "A Sebba"
Article Synopsis
- The study aimed to describe the characteristics and clinical status of patients with psoriatic arthritis (PsA) who are being treated with ixekizumab, a medication used for this condition.
- Data was collected through a survey involving 68 rheumatologists and 275 patients, focusing on demographics, disease severity, treatment satisfaction, and symptom burden before and after starting ixekizumab.
- Results showed significant improvements in clinical features such as pain, fatigue, and joint counts after starting ixekizumab, indicating its effectiveness in real-world settings, supporting findings from clinical trials.
Objective: Randomized controlled trials (RCTs) in biologic-naïve rheumatoid arthritis (RA) patients with high disease activity and inadequate response/intolerance to methotrexate have shown interleukin-6 (IL-6) receptor inhibitors (IL-6Ri) to be superior to tumor necrosis factor inhibitors (TNFi) as monotherapy. This observational study aimed to compare the effectiveness of TNFi vs IL-6Ri as mono- or combination therapy in biologic/targeted synthetic (b/ts) -experienced RA patients with moderate/high disease activity.
Methods: Eligible b/ts-experienced patients from the CorEvitas RA registry were categorized as TNFi and IL-6Ri initiators, with subgroups initiating as mono- or combination therapy.
Article Synopsis
- In rheumatoid arthritis (RA) patients, a condition called disproportionate articular pain (DP) causes joint pain that is more severe than the swelling suggests, affecting about 23% of patients in a study.
- The study analyzed data from various trials to assess the impact of sarilumab, an IL-6 inhibitor, on patients with and without DP, revealing that those treated with sarilumab were more likely to become DP-free.
- Results indicate that while inflammation is a factor in RA, other mechanisms may also play a role in causing DP, highlighting potential pathways for further investigation in treatment strategies.
Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis.
Open Access Rheumatol
March 2021
Pain is a major and common symptom reported as a top priority in patients with rheumatoid arthritis (RA). Intuitively, RA-related pain is often considered to be a natural consequence of peripheral inflammation, so treatment of RA is expected to manage pain concurrently as part of inflammation control. However, pain in patients with RA can be poorly correlated with objective measures of inflammation, for example, in patients who are otherwise in remission.
View Article and Find Full Text PDFPain is a manifestation of rheumatoid arthritis (RA) that is mediated by inflammatory and non-inflammatory mechanisms and negatively affects quality of life. Recent findings from a Phase 3 clinical trial showed that patients with RA who were treated with a Janus kinase 1 (Jak1) and Janus kinase 2 (Jak2) inhibitor achieved significantly greater improvements in pain than those treated with a tumor necrosis factor blocker; both treatments resulted in similar changes in standard clinical measures and markers of inflammation. These findings suggest that Jak1 and Jak2 inhibition may relieve pain in RA caused by inflammatory and non-inflammatory mechanisms and are consistent with the overarching involvement of the Jak-signal transducer and activator of transcription (Jak/STAT) pathway in mediating the action, expression, and regulation of a multitude of pro- and anti-inflammatory cytokines.
View Article and Find Full Text PDF